Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine

Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine

Personalized cancer vaccines hold promises for future cancer therapy. Targeting neoantigens is perceived as more beneficial compared to germline, non-mutated antigens. However, it is a practical challenge to identify and vaccinate patients with neoantigens. Here we asked whether two neoantigens are...

Full description

Bibliographic Details
Main Authors: Mona O. Mohsen, Monique Vogel, Carsten Riether, Julius Muller, Silvia Salatino, Nicola Ternette, Ariane C. Gomes, Gustavo Cabral-Miranda, Aadil El-Turabi, Christiane Ruedl, Thomas M. Kundig, Said Dermime, Alexander Knuth, Daniel E. Speiser, Martin F. Bachmann
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-05-01
Series:Frontiers in Immunology
Subjects:
virus-like particles
vaccine
personalized
melanoma
neoantigen
mutated
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2019.01015/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2019.01015/full

Similar Items